Bank OZK Buys Shares of 11,793 Amgen Inc. $AMGN

Key Points

• Bank OZK acquired 11,793 Amgen shares worth approximately $4.27 million during the second quarter, making Amgen about 1.3% of its portfolio. Institutional investors collectively own 76.5% of Amgen’s stock.
• Amgen beat quarterly expectations with $6.29 in EPS and $10.05 billion in revenue, up 9.5% year over year. The company also declared a quarterly dividend of $2.52, equivalent to a 2.3% annualized yield.
• Tezspire delivered positive Phase 3 results in eosinophilic esophagitis, potentially expanding its commercial opportunity, although Amgen also ended a Crohn’s disease research collaboration. Analysts maintain a consensus “Hold” rating with an average price target of $380.43.

Bank OZK acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 11,793 shares of the medical research company's stock, valued at approximately $4,270,000. Amgen makes up about 1.3% of Bank OZK's portfolio, making the stock its 22nd biggest position.

Other large investors also recently made changes to their positions in the company. Brighton Jones LLC raised its stake in Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company's stock valued at $7,159,000 after purchasing an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC boosted its stake in Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company's stock worth $331,000 after buying an additional 114 shares in the last quarter. Schnieders Capital Management LLC. increased its holdings in Amgen by 29.3% in the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company's stock valued at $7,220,000 after buying an additional 5,853 shares during the period. Main Street Financial Solutions LLC raised its stake in shares of Amgen by 11.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company's stock valued at $1,141,000 after buying an additional 416 shares in the last quarter. Finally, Ieq Capital LLC raised its stake in shares of Amgen by 5.1% in the 2nd quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company's stock valued at $15,120,000 after buying an additional 2,611 shares in the last quarter. Institutional investors own 76.50% of the company's stock.

Insiders Place Their Bets

In other news, SVP Rachna Khosla sold 1,252 shares of the firm's stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the transaction, the senior vice president directly owned 6,404 shares in the company, valued at $2,666,817.72. This trade represents a 16.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares of the company's stock, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 6,222 shares of company stock valued at $2,540,926 in the last ninety days. Company insiders own 0.85% of the company's stock.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Tezspire posted strong Phase 3 results in eosinophilic esophagitis (EoE). The drug met both co-primary and all key secondary endpoints, producing statistically significant and clinically meaningful improvements in tissue inflammation and difficulty swallowing. Benefits were sustained through 52 weeks, supporting a potential third approved indication beyond asthma and chronic rhinosinusitis with nasal polyps. Tezspire Phase 3 results
• Positive Sentiment: The EoE opportunity could materially expand Tezspire’s commercial potential. Analysts and industry commentators view EoE as a possible blockbuster market, potentially allowing Amgen and partner AstraZeneca to compete more directly with established biologics such as Dupixent. Regulatory filing and approval remain necessary before the opportunity can translate into revenue. Tezspire EoE market opportunity
• Neutral Sentiment: Amgen began a Phase 1 study of AMG 691 aimed at a potentially important Asian market. The trial could add a long-term growth asset, but it is at an early stage and provides limited near-term earnings visibility. AMG 691 Phase 1 trial
• Negative Sentiment: Amgen ended its Crohn’s disease research collaboration with TScan Therapeutics. The decision removes an exclusive effort to identify and develop T-cell targets in inflammatory bowel disease, narrowing one element of Amgen’s early pipeline and highlighting uncertainty around its partnership strategy. Amgen ends Crohn’s disease partnership

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $436.99 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 1-year low of $269.77 and a 1-year high of $447.03. The stock has a market capitalization of $236.25 billion, a P/E ratio of 27.16, a P/E/G ratio of 3.18 and a beta of 0.41. The business has a 50-day moving average price of $386.75 and a two-hundred day moving average price of $364.23.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. During the same quarter last year, the firm earned $6.02 EPS. The company's revenue for the quarter was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities analysts predict that Amgen Inc. will post 22.92 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. Amgen's dividend payout ratio (DPR) is presently 62.65%.

Analysts Set New Price Targets

Several brokerages have recently weighed in on AMGN. BMO Capital Markets lifted their target price on shares of Amgen from $400.00 to $450.00 and gave the company an "outperform" rating in a research report on Wednesday, August 5th. Morgan Stanley reaffirmed an "overweight" rating and set a $362.00 price objective on shares of Amgen in a report on Wednesday, August 19th. Oppenheimer upped their price objective on Amgen from $400.00 to $450.00 and gave the company an "outperform" rating in a research note on Wednesday, August 5th. Barclays raised their target price on Amgen from $360.00 to $380.00 and gave the stock an "equal weight" rating in a research report on Friday, August 14th. Finally, Mizuho boosted their price target on Amgen from $303.00 to $352.00 and gave the company a "neutral" rating in a research note on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $380.43.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source